- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00357552
Safety and Effectiveness of Lopinavir/Ritonavir in Individuals Who Have Failed Prior HIV Therapy
A Pilot Study of Lopinavir/Ritonavir in Participants Experiencing Virologic Relapse on NNRTI-Containing Regimens
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Standard effective antiretroviral therapy for HIV infected individuals includes three-drug combinations of two nucleoside reverse transcriptase inhibitors (NRTIs) with either a PI or an NNRTI. However, three-drug regimens may not be ideal in resource-limited settings, where viral load and resistance testing may not be readily available. The purpose of this study is to evaluate the safety and efficacy of the PI LPV/r alone in treatment-experienced, PI-naive HIV infected individuals who are experiencing virologic failure on three-drug regimens.
This study will last 104 weeks. All participants will receive LPV/r twice daily for up to 104 weeks. Participants who experience virologic failure will receive emtricitabine/tenofovir disoproxil fumarate once daily in addition to LPV/r twice daily for the remainder of the study.
There will be 16 study visits for participants on LPV/r monotherapy and 12 study visits for participants who have intensified LPV/r with emtricitabine/tenofovir disoproxil fumarate. Blood collection and clinical assessment will occur at all visits; urine collection and resistance testing will occur at selected visits.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
-
Chennai, Indien
- Y.R.G Ctr, for AIDS Research and Education (11701)
-
-
-
-
-
Lilongwe, Malawi
- University of North Carolina Lilongwe CRS (12001)
-
-
-
-
Gauteng
-
Johannesburg, Gauteng, Südafrika
- Wits HIV CRS (11101)
-
-
-
-
-
Moshi, Tansania
- Kilimanjaro Christian Medical CRS
-
-
-
-
-
Chiang Mai, Thailand, 50202
- Chiang Mai University ACTG CRS (11501)
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria for Step 1 Participants:
- HIV infected
- Continuous treatment with a three-drug, NNRTI-containing regimen for at least 6 months prior to study entry
- Viral load of 1,000 copies/ml or greater and less or equal to 200,000 copies/ml obtained within 30 days of study entry
- Negative pregnancy test within 48 hours of study entry
- Willing to use acceptable forms of contraception for the duration of the study
Laboratory values obtained within 30 days of study entry:
- Hemoglobin greater or equal to 8.0 g/dL
- Platelet count greater or equal to 50,000/mm3
- Estimated Creatinine Clearance greater or equal to 60 mL/min x ULN
- AST (SGOT), ALT (SGPT) and alkaline phosphatase < 3 x ULN
- Total bilirubin less or equal to 2.5 x ULN
- Ability and willingness of participant or legal guardian/representative to give informed consent
Inclusion Criteria for Step 2 Participants:
- Virologic failure on LPV/r monotherapy defined as viral load of 400 copies/ml or greater after 24 consecutive weeks on LPV/r monotherapy OR virologic failure after initial viral suppression on LPV/r monotherapy
- Estimated creatinine clearance of 60 ml/min or greater
- Negative pregnancy test within 48 hours of entry into Step 2
- Willing to use acceptable forms of contraception for the duration of the study
Exclusion Criteria for All Participants:
- Breastfeeding
- Known allergy or sensitivity to study drugs
- Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with study adherence to study requirements
- History of chronic hepatitis B infection
Exclusion Criteria for Step I Participants:
- Prior use of any protease inhibitor treatment
- Acute therapy for any serious medical condition within 14 days of study entry. For ongoing or chronic therapy, the participant must be on the treatment regimen for at least 14 days, and clinically stable prior to entry. If a potential participant has TB and has received treatment for more than 2 weeks, the TB treatment would have to be modified to include a rifabutin-containing regimen. TB compatible syndromes will also be carefully evaluated prior to entry.
Exclusion Criteria for Step 2 Participants:
- Active opportunistic infection, including tuberculosis (TB)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: LPV/r monotherapy
Participants will receive lopinavir/ritonavir twice daily for up to 104 weeks.
Upon confirmation of virologic failure, emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) once a day will be added to their regimen.
|
Once daily
Andere Namen:
Twice daily
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Percentage of Enrolled Participants With Virologic Success at Week 24 on LPV/r Monotherapy
Zeitfenster: From study entry to week 24
|
Virologic success at week 24 on LPV/r monotherapy was defined as remaining on LPV/r monotherapy at week 24 without prior virologic failure.
Virologic failure was met with either of these two conditions: (i) failure to suppress HIV-1 RNA to < 400 copies/mL by week 24 or (ii) confirmed HIV-1 RNA >= 400 copies/mL after confirmed HIV-1 RNA < 400 copies/mL.
|
From study entry to week 24
|
Probability of Grade 3 or 4 Sign or Symptom, or Laboratory Toxicity Over 24 Weeks on Study.
Zeitfenster: From study entry to week 24
|
Probability of Grade 3 or 4 sign or symptom, or laboratory toxicity over 24 weeks on study using Kaplan-Meier estimates of the cumulative probability of Grade 3 or 4 sign or symptom, or laboratory toxicity at week 24.
Grading of adverse events (signs and symptoms and laboratory toxicities) was according to Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, December 2004.
|
From study entry to week 24
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Number of Screened Subjects With at Least One NNRTI, or NRTI-associated Resistance Mutation at A5230 Screening.
Zeitfenster: Screening
|
Number of screened subjects with at least one NNRTI, or NRTI-associated resistance mutation.
Resistance interpretations used the November 30, 2011 Stanford algorithm.
|
Screening
|
Time to Treatment Failure, Defined as the First Occurrence of Death, Disease Progression, or Virologic Failure.
Zeitfenster: Study entry to Week 104
|
25th percentile in weeks from study entry to treatment failure, defined as the first occurrence of death, disease progression, or virologic failure.
Virologic failure was defined as HIV-1 >= 400 copies/mL after week 24 or 2 consecutive HIV-1 RNA >= 400 copies/mL after week 16 following suppression on LPV/r monotherapy.
|
Study entry to Week 104
|
Number of Participants With Study-targeted Diagnoses and Clinical Events
Zeitfenster: Study entry to week 104
|
Cardiac disorders, Infections and infestations, Metabolism and nutrition disorders, Neoplasms benign, malignant and unspecified (including cysts and polyps), Pregnancy, puerperium and perinatal conditions, Vascular disorders, were specified a priori as study-targeted events by the study chair.
|
Study entry to week 104
|
Number of Subjects With at Least One New PI-associated Resistance Mutation at Time of Virologic Failure.
Zeitfenster: At time of virologic failure
|
Number of subjects with at least one new PI-associated resistance mutation at time of virologic failure.
Resistance interpretations used the May 6, 2009 Stanford algorithm.
|
At time of virologic failure
|
Percentage of Subjects Reporting Not Skipping Medications in the Last Month.
Zeitfenster: Study entry and weeks 2, 4, 8, 12, 16, 20, and 24
|
The percentage of subjects reporting never missing medications in the last month.
|
Study entry and weeks 2, 4, 8, 12, 16, 20, and 24
|
Time to First New Grade 3 or 4 Sign or Symptom or Laboratory Toxicity Following LPV/r Intensification
Zeitfenster: From LPV/r intensification to week 104
|
25th percentile in weeks from study entry to first new grade 3 or 4 sign or symptom or laboratory toxicity following LPV/r intensification.
Grading of adverse events (signs and symptoms and laboratory toxicities) was according to Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, December 2004.
|
From LPV/r intensification to week 104
|
Level of HIV-1 RNA as Ascertained From Paired DBS and Plasma
Zeitfenster: At study entry and weeks 24 and 48
|
Proportion of DBS samples with HIV-1 RNA level <= 400 copies/mL, proportion of plasma samples with HIV-1 RNA level <= 400 copies/mL and proportion of paired DBS and plasma samples that are concordant (both <= 400 copies/mL or both > 400 copies/mL).
Results are pooled over 4 different storage temperature conditions (-80C, -20C, 4C and room temperature).
|
At study entry and weeks 24 and 48
|
HIV-1 Viral Sequence as Ascertained From Paired DBS and Plasma
Zeitfenster: At study entry and virologic failure
|
HIV-1 viral sequencing as ascertained from paired DBS and plasma
|
At study entry and virologic failure
|
Proportion of Participants With Plasma HIV-1 RNA Levels < 400 Copies/mL From Baseline to Week 104
Zeitfenster: At Weeks 0, 12, 16, 20, 24, 32, 40, 48, 56, 68, 80, 92, 104
|
At Weeks 0, 12, 16, 20, 24, 32, 40, 48, 56, 68, 80, 92, 104
|
|
Change in CD4+ Cell Counts From Study Entry to Week 104
Zeitfenster: Study entry and week 104
|
Study entry and week 104
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienstuhl: Nagalingeswaran Kumarasamy, MBBS, PhD, Y. R. Gaitonde Centre for AIDS Research and Education
- Studienstuhl: John Bartlett, MD, Division of Infectious Diseases, Duke University Medical Center
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Arribas JR, Pulido F, Delgado R, Lorenzo A, Miralles P, Arranz A, Gonzalez-Garcia JJ, Cepeda C, Hervas R, Pano JR, Gaya F, Carcas A, Montes ML, Costa JR, Pena JM. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):280-7. doi: 10.1097/01.qai.0000180077.59159.f4.
- Campo RE, Lalanne R, Tanner TJ, Jayaweera DT, Rodriguez AE, Fontaine L, Kolber MA. Lopinavir/ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patients. AIDS. 2005 Mar 4;19(4):447-9. doi: 10.1097/01.aids.0000161777.38438.ed. No abstract available.
- Joly V, Descamps D, Peytavin G, Touati F, Mentre F, Duval X, Delarue S, Yeni P, Brun-Vezinet F. Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs. Antimicrob Agents Chemother. 2004 Jan;48(1):172-5. doi: 10.1128/AAC.48.1.172-175.2004.
- Bartlett JA, Ribaudo HJ, Wallis CL, Aga E, Katzenstein DA, Stevens WS, Norton MR, Klingman KL, Hosseinipour MC, Crump JA, Supparatpinyo K, Badal-Faesen S, Kallungal BA, Kumarasamy N. Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings. AIDS. 2012 Jul 17;26(11):1345-54. doi: 10.1097/QAD.0b013e328353b066.
- Kumarasamy N, Aga E, Ribaudo HJ, Wallis CL, Katzenstein DA, Stevens WS, Norton MR, Klingman KL, Hosseinipour MC, Crump JA, Supparatpinyo K, Badal-Faesen S, Bartlett JA. Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230. Clin Infect Dis. 2015 May 15;60(10):1552-8. doi: 10.1093/cid/civ109. Epub 2015 Feb 18.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- RNA-Virusinfektionen
- Viruserkrankungen
- Infektionen
- Durch Blut übertragene Infektionen
- Übertragbare Krankheiten
- Sexuell übertragbare Krankheiten, viral
- Sexuell übertragbare Krankheiten
- Lentivirus-Infektionen
- Retroviridae-Infektionen
- Immunologische Mangelsyndrome
- Erkrankungen des Immunsystems
- HIV-Infektionen
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antiinfektiva
- Antivirale Mittel
- Reverse-Transkriptase-Inhibitoren
- Inhibitoren der Nukleinsäuresynthese
- Enzym-Inhibitoren
- Anti-HIV-Agenten
- Antiretrovirale Mittel
- Protease-Inhibitoren
- Cytochrom P-450 CYP3A-Inhibitoren
- Cytochrom-P-450-Enzym-Inhibitoren
- HIV-Protease-Inhibitoren
- Virale Protease-Inhibitoren
- Tenofovir
- Emtricitabin
- Ritonavir
- Lopinavir
- Wirkstoffkombination Emtricitabin, Tenofovir Disoproxil Fumarat
Andere Studien-ID-Nummern
- ACTG A5230
- 1U01AI068636 (US NIH Stipendium/Vertrag)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur HIV-Infektionen
-
Duke UniversityAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)Vereinigte Staaten
-
Catholic University of the Sacred HeartAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)
-
Abbott Medical DevicesThoratec CorporationAbgeschlossenDriveline Heart-assisted Device Related InfectionVereinigte Staaten
-
Princess Maxima Center for Pediatric OncologyUMC Utrecht; Dutch Cancer SocietyRekrutierungCentral Line-associated Bloodstream Infection (CLABSI)Niederlande
-
University of MalayaTeleflexRekrutierungCLABSI – Central Line Associated Bloodstream InfectionMalaysia
-
National Taiwan University Hospital Hsin-Chu BranchAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)
-
Johns Hopkins UniversityAbgeschlossenCLABSI – Central Line Associated Bloodstream InfectionVereinigte Staaten
-
National Taiwan University HospitalAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)Taiwan
-
Princess Anna Mazowiecka Hospital, Warsaw, PolandNutricia FoundationAktiv, nicht rekrutierendWachstumsfehler | CLABSI – Central Line Associated Bloodstream InfectionPolen
-
University of ZurichNoch keine RekrutierungCentral Line-associated Bloodstream Infection (CLABSI) | Katheterbedingte Blutstrominfektion
Klinische Studien zur Emtricitabine/Tenofovir disoproxil fumarate
-
Emory UniversityCenters for Disease Control and PreventionAbgeschlossenHIV-InfektionenVereinigte Staaten
-
University of Colorado, DenverAbgeschlossenGesunde Freiwillige | Pharmakokinetik
-
Gilead SciencesAbgeschlossenHIV-InfektionenVereinigte Staaten
-
International Partnership for Microbicides, Inc.Gilead SciencesZurückgezogen
-
Gilead SciencesAbgeschlossen
-
Gilead SciencesAbgeschlossenHIV-Infektionen | Erworbenes ImmunschwächesyndromVereinigte Staaten
-
Midtown Medical Center, Tampa, FLGilead SciencesAbgeschlossenHIV | Schlafstörungen | AIDS
-
Fred Hutchinson Cancer CenterNational Institute on Drug Abuse (NIDA); Asociación Civil Impacta Salud y Educación... und andere MitarbeiterAbgeschlossen
-
Gilead SciencesAbgeschlossenHIV-Infektionen | HIVVereinigte Staaten, Puerto Rico
-
Vancouver Infectious Diseases CentreGilead Sciences; Regina General HospitalUnbekanntHIV | Illegaler DrogenkonsumentKanada